Login to Your Account



ERISA class action challenges U.S. drug pricing scheme

By Mari Serebrov
Regulatory Editor

Wednesday, August 30, 2017

Amid all the political and industry pontificating and finger-pointing on ever-increasing U.S. drug prices, patients are turning to the courts for relief, using a class action aimed at pharmaceutical benefit managers (PBMs) as their pulpit of choice.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription